MULTIFUGE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Multifuge, and when can generic versions of Multifuge launch?
Multifuge is a drug marketed by Bluline and is included in one NDA.
The generic ingredient in MULTIFUGE is piperazine citrate. There are eighteen drug master file entries for this compound. Additional details are available on the piperazine citrate profile page.
Summary for MULTIFUGE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 50 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MULTIFUGE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for MULTIFUGE
US Patents and Regulatory Information for MULTIFUGE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bluline | MULTIFUGE | piperazine citrate | SYRUP;ORAL | 009452-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |